Gossypetin
Based on 4 publication(s) in Google Scholar
Gossypetin is a hexahydroxylated flavonoid and is a potent mitogen-activated protein kinase kinase (MKK)3 and MKK6 inhibitor with strongly attenuates the MKK3/6-p38 signaling pathway, has various pharmacological activities, including antioxidant, antibacterial and anticancer activities.
For research use only. We do not sell to patients.
- Purity: 99.0%
- CAS No.: 489-35-0
- Formula: C15H10O8
- Molecular Weight:318.24
-
Storage:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Gossypetin
MoreAll MEK Isoforms
More
Biological Activity
|
p38 MAP kinase |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Huh-7 | CC50 |
>50 μM
Compound: 36
|
Cytotoxicity against human Huh7.5.1 cells by MTT assay
Cytotoxicity against human Huh7.5.1 cells by MTT assay
|
[PMID: 22445328] |
| Huh-7 | EC50 |
47 μM
Compound: 36
|
Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay
Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay
|
[PMID: 22445328] |
| MDCK | CC50 |
283 μM
Compound: 6
|
Cytotoxicity against MDCK cells after 48 hrs by MTT assay
Cytotoxicity against MDCK cells after 48 hrs by MTT assay
|
[PMID: 19729316] |
| MDCK | EC50 |
36.3 μM
Compound: 6
|
Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect
Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect
|
[PMID: 19729316] |
| MDCK | EC50 |
43 μM
Compound: 6
|
Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect
Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect
|
[PMID: 19729316] |
Gossypetin (20-60 μM; 48 hours; KYSE30, KYSE450 and KYSE510 cells) treatment significantly inhibits anchorage-dependent esophageal cancer cell growth in dose dependent manner. Gossypetin strongly suppresses anchorage-independent cell growth in esophageal cancer cells[1].
Gossypetin (60 μM; 3 hours; KYSE30 and KYSE410 cells) treatment strongly inhibits p38 activity in a dose-dependent manner and confirms that Gossypetin directly suppresses MKK3 or MKK6 activity[1].
Gossypetin (20-40 μM; 48 hours; KYSE450 and KYSE510 cells) treatment reduces S phase and induces G2 phase cell cycle arrest in a dose-dependent manner[1].
Gossypetin (20-40 μM; 72 hours; esophageal cancer cells) treatment induces intrinsic apoptosis of esophageal cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:KYSE30, KYSE450 and KYSE510 cells
-
Concentration:20 μM, 40 μM, 60 μM
-
Incubation Time:48 hours
-
Result:Anchorage-dependent esophageal cancer cell growth was significantly inhibited.
-
Cell Line:KYSE30 and KYSE410 ccells
-
Concentration:60 μM
-
Incubation Time:3 hours
-
Result:p38 activity was strongly inhibited in a dose-dependent manner.
-
Cell Line:KYSE450 and KYSE510 cells
-
Concentration:20 μM, 40 μM
-
Incubation Time:48 hours
-
Result:Reduced S phase and induces G2 phase cell cycle arrest in a dose-dependent manner.
-
Cell Line:Esophageal cancer cells
-
Concentration:20 μM, 40 μM
-
Incubation Time:72 hours
-
Result:Induced apoptosis of esophageal cancer cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Severe combined immunodeficiency (SCID) female mice (6-9 weeks old) injection with esophageal cancer tissue[1]
-
Dosage:100 mg/kg
-
Administration:Oral administration; 5 times per week; for 21 days
-
Result:Suppressed patient-derived esophageal xenograft tumor growth in an in vivo mouse model.
Chemical Information
-
CAS No. 489-35-0
-
Appearance Solid
-
Molecular Weight 318.24
-
Formula C15H10O8
-
Color Light yellow to yellow
-
SMILES
O=C1C(O)=C(OC2=C1C(O)=CC(O)=C2O)C3=CC(O)=C(C=C3)O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cell Discov
MAPK13 phosphorylates PHGDH and promotes its degradation via chaperone-mediated autophagy during liver injury. [Abstract]2025 Feb 18;11(1):15. PMID: 39962071 -
Cancer Lett
Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer. [Abstract]2025 Aug 29:633:218010. PMID: 40886822 -
Int J Biol Macromol
Rabies virus matrix protein hijacks the TGF-beta activated kinase 1 binding protein 2-p38 mitogen-activated protein kinase pathway to inhibit apoptosis and promote viral replication. [Abstract]2026 Mar:349:150991. PMID: 41713525 -
Solvent & Solubility
DMSO : 125 mg/mL (392.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1423 mL | 15.7114 mL | 31.4228 mL | 78.5571 mL |
| 5 mM | 0.6285 mL | 3.1423 mL | 6.2846 mL | 15.7114 mL | |
| 10 mM | 0.3142 mL | 1.5711 mL | 3.1423 mL | 7.8557 mL | |
| 15 mM | 0.2095 mL | 1.0474 mL | 2.0949 mL | 5.2371 mL | |
| 20 mM | 0.1571 mL | 0.7856 mL | 1.5711 mL | 3.9279 mL | |
| 25 mM | 0.1257 mL | 0.6285 mL | 1.2569 mL | 3.1423 mL | |
| 30 mM | 0.1047 mL | 0.5237 mL | 1.0474 mL | 2.6186 mL | |
| 40 mM | 0.0786 mL | 0.3928 mL | 0.7856 mL | 1.9639 mL | |
| 50 mM | 0.0628 mL | 0.3142 mL | 0.6285 mL | 1.5711 mL | |
| 60 mM | 0.0524 mL | 0.2619 mL | 0.5237 mL | 1.3093 mL | |
| 80 mM | 0.0393 mL | 0.1964 mL | 0.3928 mL | 0.9820 mL | |
| 100 mM | 0.0314 mL | 0.1571 mL | 0.3142 mL | 0.7856 mL |
Gossypetin Related Classifications
HY-119917 Related Classifications
Powered by Bioz